Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
narazaciclib + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Traws Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Narazaciclib + dexamethasone is an investigational combination therapy being evaluated for the treatment of relapsed and/or refractory multiple myeloma. Narazaciclib (ON 123300) is a first-in-class, multi-targeted oral kinase inhibitor that targets cyclin-dependent kinases 4 and 6 (CDK4/6) and AMPK-related protein kinase 5 (ARK5/NUAK1), as well as CSF1R, c-Kit, and FLT3. By inhibiting these pathways, narazaciclib suppresses DNA synthesis by preventing the G1-S phase transition and induces mitochondria-mediated apoptosis in cancer cells. Dexamethasone is a potent synthetic glucocorticoid that provides anti-inflammatory and immunosuppressive effects, commonly used in combination with targeted agents to enhance therapeutic efficacy in plasma cell dyscrasias. This specific combination is being investigated in a Phase I/II clinical trial led by Adriana Rossi at Weill Cornell Medicine.
- Other names
- ON 123300 + dexamethasonenarazaciclib and dexamethasone
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)GR (Glucocorticoid receptor)NUAK1 (NUAK family SNF1-like kinase 1)
Beyond the preview
Go deeper on narazaciclib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on narazaciclib + dexamethasone.